Skip to main content

Assessment of CCM in HF With Higher Ejection Fraction

Recruiting · Not applicable · NCT05064709

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure

At a glance

Research payments reported, 2025
$915,340
U.S. investigators named
74
Sites paid
78
Planned or actual enrollment
1,500

About the trial

Sponsor
Impulse Dynamics
Tested
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System (device), OPTIMIZER™ Smart Mini System (device)
Dates
Started 2022-02-03; completion 2029-02-01
Results posted
Not yet

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Impulse Dynamics (USA) Inc. reported $915,340 in research payments for this study in 2025 (442 payments).

Products named: Optimizer

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.